<DOC>
	<DOCNO>NCT02442362</DOCNO>
	<brief_summary>This study design compare efficacy safety aclitaxel/oxaliplatin/fluorouracil ( TOF ) regimen S-1/oxaliplatin ( SOX ) regimen metastatic gastric cancer ( GC ) patient .</brief_summary>
	<brief_title>TOF Versus SOX Metastatic Gastric Cancer</brief_title>
	<detailed_description>Gastric carcinoma rank second among common cause cancer death worldwide , especial high prevalence Asia . Gastric cancer third common cancer China incidence rate death rate gastric cancer Jiangsu Province especially high national average . Surgical resection prefer treatment gastric cancer , approximately two-thirds patient metastatic disease time diagnosis . Prognosis patient poor , median survival time 3 5 month without treatment report 5-year survival rate 9.4 % . Even receive curative gastrectomy , 60 % mGC patient develop local recurrence distant metastasis . For advanced-stage patient inoperable gastric tumor , chemotherapy consider effective treatment option efficacy postoperative chemotherapy acknowledge . However , worldwide consensus standard chemotherapy regimens yet establish . The prognosis gradually improve advance chemotherapy regimen , yet satisfactory.Among various regimen , combination paclitaxel/oxaliplatin/fluorouracil ( TOF ) regimen S-1/oxaliplatin ( SOX ) regimen become two important one . Paclitaxel bind microtubule induces hyperstabilization lead cell cycle arrest apoptosis . The response rate GC patient paclitaxel 20 % -25 % . Oxaliplatin third-generation diaminocyclohexane platinum compound wide range antitumor activity , appear good safety profile cisplatin . The response rate mGC patient FOLFOX-4 regimen 38 % -43 % . S-1 oral anti-cancer agent compose tegafur , 5-chloro-2,4-dihydroxypyridine , oteracil potassium . The apply S-1 adjuvant chemotherapy mGC improve overall survival ( OS ) relapse-free survival . A meta-analysis show OS favor S-1-based chemotherapy 5-FU-based chemotherapy mGC . S-1 plus oxaliplatin ( SOX ) show non-inferiority S-1 plus cisplatin PFS treatment well tolerated patient mGC . No study available compare efficacy safety TOF SOX regimen . So investigator perform present randomize , control study compare efficacy safety two regimen mGC patient .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1. pathologically confirm mGC ( stage IV ) 2. age 20 80 year 3. measurable assessable lesion image study accord RECIST guideline 21 4. prior chemotherapy except postoperative adjuvant chemotherapy 12 month entry study 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status score less 3 6. hepatic function total bilirubin ≤ 1.5 × institutional upper limit normal value , aspartate aminotransferase/alanine aminotransferase ≤ 2.5 × institutional upper limit normal value , alkaline phosphatase ≤ 2.5 × institutional upper limit normal value renal function ( serum creatinine level ≤ 1.5 mg/dL creatinine clearance ≥ 50 ml/min ) adequate bone marrow function ( hemoglobin level ≥ 90 g/L , white blood cell count 410×109/L , neutrophil count ≥ 2×109/L , platelet count ≥ 100×109/L ) 7. estimate life expectancy 3 month 8. secondary malignant tumor . 1. preexisted peripheral toxicity ≥ grade 2 National Cancer Institute Common Toxicity Criteria 2. concurrent prior malignancy 3. central nervous system metastases 4. concurrent treatment interfere study evaluation 5. active infection 6. uncontrolled underlying medical condition would impair ability patient receive plan treatment 7. inadequate calorie fluid intake 8. pregnant , breastfeed woman woman childbearing potential without adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>